Future investigation and more selective drug development will be necessary to determine clinical applicability of KDM5A inhibitors especially in accelerated CML, for which few therapeutic options exist. This evidence concerns the gene KDM5A and chronic myelogenous leukemia, BCR-ABL1 positive.